The Danish company JN MEAT INTERNATIONAL once again comes out on top being the world’s best steak producer
16.11.2021 17:29:00 EET | Business Wire | Press release
After being crowned best steak producer in the world 2018 and 2019, JN MEAT INTERNATIONAL once again came out on top at the World Steak Challenge 2021 (after the 2020 competition was cancelled due to Covid)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005983/en/
The Danish company JN MEAT INTERNATIONAL once again comes out on top being the world’s best steak producer. (Photo: Business Wire)
Almost 400 steaks from 23 countries competed this year in Dublin November 10th 2021.
During a 12 hour session a professional jury together with a consumer-jury judged the many steaks in terms of taste, tenderness and appearance.
The juries found that a sirloin steak from the SASHI series from JN MEAT INTERNATIONAL was the overall best of all steaks.
As a result, this steak was crowned the best in the world, and the company the best steak-producer in the world for the third time in a row, after also winning in 2018 and 2019.
The awarded steak is a product in the SASHI series of quality beef which consists of beef with different characteristics and origins.
Amongst these brands are Freygaard-Nordic Nature Beef origin Finland, Prussian Black origin Germany, Cloverfield origin UK/Ireland and SABOR origin Argentina.
The founder of JN MEAT INTERNATIONAL, John SASHI Nielsen made the following comments after the announcement of the winner 10.11-2021:
So happy and proud that despite being in a lower division in terms of size and budget once again we are playing in the Champions League… of beef. I am also very pleased to learn that most of us competing at the contest share the same passion and goal, which is being able to offer beef with a high eating quality but at the same time making it sustainably. No doubt what the future holds for our industry, being that less is more. Current and future generations will still eat beef, but much less and much better beef, I am convinced. As a consequence, at JN MEAT INTERNATIONAL we shall continue to follow our motto: EAT LESS CHOOSE BETTER…
Facts
JN Meat International has 70 employees and produces a large number of its own meat cuts for both Danish and international customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005983/en/
Contact information
Contacts:
John Sashi Nielsen, Founder and CEO
Mobil +45 4040 4082
Mail: jn@jnmeat.dk
Steffen Nagel, Head of Global Sales & Export
Mobil +45 2161 5018
Mail:
sn@jnmeat.dk
JN MEAT INTERNATIONAL
Elmedalsvej 8
DK 4200 Slagelse
Tlf.: +45 5858 0200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom